1
|
Vasconcelos PENS, Seguin CS, Barbeiro ADS, Zambon L, Honma HN, Perroud MW, Geraldo MV, Pincinato EDC, Moriel P. hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel. Oncol Lett 2024; 27:219. [PMID: 38586206 PMCID: PMC10995660 DOI: 10.3892/ol.2024.14350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Accepted: 01/22/2024] [Indexed: 04/09/2024] Open
Abstract
Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first-line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse events, particularly hematological reactions. Studies on new biomarkers related to these adverse events, such as circulating microRNAs (miRNAs/miRs), are important for optimizing the quality of life of patients. miRNAs have high stability in several biological fluids and they have specific expressions in different tissues or pathologies. Thus, the present study aimed to assess the relationship between circulating miRNAs and adverse hematologic reactions caused by treatment with carboplatin + paclitaxel in patients with lung cancer. Blood was collected from patients before and 15 days after chemotherapy for hematological adverse reaction analysis, microarray and quantitative (q)PCR validation. Adverse reactions were classified according to the Common Terminology Criteria for Adverse Events v4.0. Microarray analysis was performed using plasma from six patients without anemia and six patients with anemia, and nine miRNAs were differentially expressed. miR-1273g-3p, miR-3613-5p and miR-455-3p, identified using microarray, were assessed using qPCR in 20 patients without anemia and 26 patients with anemia. Bioinformatic analyses of miR-455-3p were performed using miRWalk, the Database for Annotation, Visualization and Integrated Discovery and GeneMania software. Microarray analysis of patients with and without anemia revealed nine significant differentially-expressed plasma miRNAs among these patients. Of these, miR-1273g-3p, miR-3613-5p and miR-455-3p were chosen for further assessment. Only miR-455-3p demonstrated a significant reduction in expression (P=0.04) between the groups before chemotherapy with carboplatin + paclitaxel. Bioinformatics analysis of miR-455-3p revealed a relationship between this miRNA and the hematopoietic pathway, particularly with respect to the RUNX family transcription factor 1 (RUNX1) and TAL bHLH transcription factor 1, erythroid differentiation factor (TAL1) genes. The most prevalent adverse reactions in patients with lung cancer treated with carboplatin + paclitaxel were hematological, particularly anemia. This adverse reaction, caused by dysfunction of the hematopoietic system, may be explained by a possible association between the important genes in this system, RUNX1 and TAL1, and hsa-miR-455-3p.
Collapse
Affiliation(s)
| | - Cecília Souto Seguin
- School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-888, Brazil
| | | | - Lair Zambon
- School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-888, Brazil
| | - Helen Naemi Honma
- School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-888, Brazil
| | - Maurício Wesley Perroud
- School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-888, Brazil
| | - Murilo Vieira Geraldo
- Institute of Biology, Universidade Estadual de Campinas, Campinas, São Paulo 13083-970, Brazil
| | | | - Patricia Moriel
- Faculty of Pharmaceutical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-871, Brazil
| |
Collapse
|
2
|
Vaz CDO, Mazetto BM, Vasconcelos PENS, Bastos LB, Cursino MA, Quintanilha JCF, Mesquita GLTV, Dos Santos APR, Jacintho BC, Oliveira JD, Annichino-Bizzacchi J, Orsi FA. Answer to "REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome". J Thromb Thrombolysis 2022; 54:191-192. [PMID: 35419746 DOI: 10.1007/s11239-022-02652-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/03/2022] [Indexed: 10/18/2022]
Affiliation(s)
- Camila de O Vaz
- Department of Pharmacology, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Bruna M Mazetto
- School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | | | | | - Maria Aparecida Cursino
- Department of Medical Sciences, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | | | | | - Ana Paula Rosa Dos Santos
- Department of Medical Sciences, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Bruna Cardoso Jacintho
- Department of Clinical Medicine, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - José Diogo Oliveira
- Department of Clinical Medicine, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Joyce Annichino-Bizzacchi
- Department of Clinical Medicine, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil.,Hematology and Hemotherapy, Center University of Campinas, Campinas, SP, Brazil
| | - Fernanda Andrade Orsi
- Hematology and Hemotherapy, Center University of Campinas, Campinas, SP, Brazil. .,Department of Pathology, School of Medical Sciences, University of Campinas, Campinas R. Tessália Vieira de Camargo, 126. Cidade Universitária, Campinas, SP, Zip Code 13083-887, Brazil.
| |
Collapse
|
3
|
de Godoy Torso N, Pereira JKN, Visacri MB, Vasconcelos PENS, Loren P, Saavedra K, Saavedra N, Salazar LA, Moriel P. Dysregulated MicroRNAs as Biomarkers or Therapeutic Targets in Cisplatin-Induced Nephrotoxicity: A Systematic Review. Int J Mol Sci 2021; 22:12765. [PMID: 34884570 PMCID: PMC8657822 DOI: 10.3390/ijms222312765] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 10/07/2021] [Accepted: 10/15/2021] [Indexed: 12/14/2022] Open
Abstract
The purpose of this systematic review was to map out and summarize scientific evidence on dysregulated microRNAs (miRNAs) that can be possible biomarkers or therapeutic targets for cisplatin nephrotoxicity and have already been tested in humans, animals, or cells. In addition, an in silico analysis of the two miRNAs found to be dysregulated in the majority of studies was performed. A literature search was performed using eight databases for studies published up to 4 July 2021. Two independent reviewers selected the studies and extracted the data; disagreements were resolved by a third and fourth reviewers. A total of 1002 records were identified, of which 30 met the eligibility criteria. All studies were published in English and reported between 2010 and 2021. The main findings were as follows: (a) miR-34a and miR-21 were the main miRNAs identified by the studies as possible biomarkers and therapeutic targets of cisplatin nephrotoxicity; (b) the in silico analysis revealed 124 and 131 different strongly validated targets for miR-34a and miR-21, respectively; and (c) studies in humans remain scarce.
Collapse
Affiliation(s)
- Nadine de Godoy Torso
- School of Medical Sciences, University of Campinas, Campinas 13083894, Brazil; (N.d.G.T.); (J.K.N.P.); (M.B.V.); (P.E.N.S.V.)
| | - João Kleber Novais Pereira
- School of Medical Sciences, University of Campinas, Campinas 13083894, Brazil; (N.d.G.T.); (J.K.N.P.); (M.B.V.); (P.E.N.S.V.)
| | - Marília Berlofa Visacri
- School of Medical Sciences, University of Campinas, Campinas 13083894, Brazil; (N.d.G.T.); (J.K.N.P.); (M.B.V.); (P.E.N.S.V.)
| | | | - Pía Loren
- Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile; (P.L.); (K.S.); (N.S.); (L.A.S.)
| | - Kathleen Saavedra
- Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile; (P.L.); (K.S.); (N.S.); (L.A.S.)
| | - Nicolás Saavedra
- Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile; (P.L.); (K.S.); (N.S.); (L.A.S.)
| | - Luis A. Salazar
- Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile; (P.L.); (K.S.); (N.S.); (L.A.S.)
| | - Patricia Moriel
- Faculty of Pharmaceutical Sciences, University of Campinas, Campinas 13083970, Brazil
| |
Collapse
|
4
|
de Oliveira Vaz C, de Moraes Mazetto Fonseca B, Nascimento Silva Vasconcelos PE, Brito Bastos L, Cursino MA, Coelho França Quintanilha J, Tripiquia Vechiatto Mesquita GL, Rosa Dos Santos AP, Cardoso Jacintho B, Oliveira JD, Annichino-Bizzachi J, Andrade Orsi F. Self-perceived quality of life of primary antiphospholipid syndrome patients using vitamin K antagonist. Lupus 2021; 30:707-714. [PMID: 33509064 DOI: 10.1177/0961203321990079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE Primary antiphospholipid syndrome (PAPS) is a chronic autoimmune disorder clinically characterized by thromboembolic events or obstetric complications. Prolonged anticoagulation therapy with vitamin K antagonists (VKA) is the treatment of choice for PAPS patients with thrombosis. However, the efficacy of VKA therapy depends on laboratory monitoring, dose adjustment, adequate lifestyle and adherence to treatment. Difficulties with VKA therapy can affect patients' self-perceived health related quality of life (HRQOL). This study aims to evaluate PAPS patients' HRQOL, therapy adherence and knowledge of treatment. METHODS A general Medical Outcome Study Short Form-36 (SF-36) and the Duke Anticoagulation Satisfaction Scale (DASS) were used to access APS-patients self-perceived HRQOL. Treatment adherence was measured by the Treatment Measure Adhesion (TMA) - oral anticoagulant version instrument, and knowledge of VKA treatment was measured using the MedTake test. RESULTS 66 PAPS patients using VKA were assessed. 63% of them were female; the mean age was 41.9 years old, approximately 60% had unprovoked venous thrombosis and one third of the patients had recurrent thrombotic events. The most impacted domain of DASS was "psychological impacts" and the factors associated to anticoagulation related poor HRQOL were: female sex, presence of arterial thrombosis and INR lability. Using the SF-36 instrument, PAPS-patients self-perceived HRQOL was poorer than that of the general Brazilian population and was associated with female sex and presence of cardiovascular risk factors. CONCLUSION Despite the high adherence to treatment and knowledge of VKA therapy, self-perceived HRQOL is poor in patients with PAPS and is mainly affected by VKA therapy. Searching for better treatment options is warranted.
Collapse
Affiliation(s)
- Camila de Oliveira Vaz
- Department of Pharmacology, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | | | | | | | - Maria Aparecida Cursino
- School of Medical Sciences, Department of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | | | | | - Ana Paula Rosa Dos Santos
- School of Medical Sciences, Department of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Bruna Cardoso Jacintho
- School of Medical Sciences, Department of Clinical Medicine, University of Campinas, Campinas, SP, Brazil
| | - José Diogo Oliveira
- School of Medical Sciences, Department of Clinical Medicine, University of Campinas, Campinas, SP, Brazil
| | - Joyce Annichino-Bizzachi
- School of Medical Sciences, Department of Clinical Medicine, University of Campinas, Campinas, SP, Brazil.,Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil
| | - Fernanda Andrade Orsi
- Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil.,School of Medical Sciences, Department of Clinical Pathology, University of Campinas, Campinas, SP, Brazil
| |
Collapse
|